PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)
NCT06710132 · RECRUITING · Phase 2
We track 2 ClinicalTrials.gov studies led by Emd Serono Research Development Institute Inc. The portfolio skews toward Phase 2 (1 trials).
2 clinical trials sponsored by Emd Serono Research Development Institute Inc.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 1 | 50% |
| Phase 3 | 1 | 50% |
Emd Serono Research Development Institute Inc currently sponsors 2 clinical trials tracked on ReadTheTrial. These span Phase 2, Phase 3.
Emd Serono Research Development Institute Inc conducts research across multiple therapeutic areas. Browse the trial listings for details.
Yes, Emd Serono Research Development Institute Inc currently has 1 trial that are actively recruiting participants. Check individual trial pages for eligibility criteria and locations.